Shares of TG Therapeutics Inc. (NASDAQ:TGTX) have been given an average recommendation of “Buy” by the eight research firms that are currently covering the stock. One investment analyst has rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average 1 year target price among analysts that have updated their coverage on the stock in the last year is $21.90.

TGTX has been the topic of a number of recent analyst reports. Roth Capital reissued a “buy” rating and set a $33.00 price target on shares of TG Therapeutics in a research note on Wednesday, August 10th. Brean Capital reissued a “buy” rating and set a $28.00 price target on shares of TG Therapeutics in a research note on Thursday, October 6th. FBR & Co reissued a “buy” rating on shares of TG Therapeutics in a research note on Monday, September 19th. S&P Equity Research reduced their price target on TG Therapeutics from $7.15 to $6.40 in a research note on Wednesday, August 24th. Finally, HC Wainwright reissued a “buy” rating and set a $18.00 price target (down previously from $22.00) on shares of TG Therapeutics in a research note on Saturday.

Several hedge funds and other institutional investors have recently modified their holdings of TGTX. BlackRock Advisors LLC raised its position in shares of TG Therapeutics by 14.5% in the second quarter. BlackRock Advisors LLC now owns 18,131 shares of the biopharmaceutical company’s stock valued at $110,000 after buying an additional 2,296 shares during the period. Mariner Wealth Advisors LLC raised its position in TG Therapeutics by 1.4% in the first quarter. Mariner Wealth Advisors LLC now owns 18,286 shares of the biopharmaceutical company’s stock valued at $156,000 after buying an additional 255 shares during the period. SECOR Capital Advisors LP bought a new position in TG Therapeutics during the second quarter valued at approximately $187,000. Emerald Acquisition Ltd. bought a new position in TG Therapeutics during the second quarter valued at approximately $190,000. Finally, Rhumbline Advisers raised its position in TG Therapeutics by 9.0% in the second quarter. Rhumbline Advisers now owns 37,547 shares of the biopharmaceutical company’s stock valued at $228,000 after buying an additional 3,107 shares during the period. 54.66% of the stock is currently owned by institutional investors and hedge funds.

TG Therapeutics (NASDAQ:TGTX) traded down 6.68% on Monday, reaching $6.15. The company had a trading volume of 382,859 shares. TG Therapeutics has a 12 month low of $5.41 and a 12 month high of $14.87. The firm has a 50-day moving average of $7.39 and a 200-day moving average of $7.37. The stock’s market capitalization is $334.90 million.

TG Therapeutics (NASDAQ:TGTX) last issued its quarterly earnings results on Monday, August 8th. The biopharmaceutical company reported ($0.33) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.29) by $0.04. TG Therapeutics had a negative return on equity of 58.77% and a negative net margin of 40,142.11%. On average, equities research analysts expect that TG Therapeutics will post ($1.22) earnings per share for the current fiscal year.

TG Therapeutics Company Profile

TG Therapeutics, Inc (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for b-cell malignancies and autoimmune diseases. The Company is developing over two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the CD20 antigen found on mature B-lymphocytes.

5 Day Chart for NASDAQ:TGTX

Receive News & Stock Ratings for TG Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics Inc. and related stocks with our FREE daily email newsletter.